UFP TECHNOLOGIES, INC. Key Metrics

2 years of history · ending 2025-12-31 · SEC EDGAR

Forensics

Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.

F-Score (Piotroski 0-9)

M-Score (Beneish; >-1.78 flags risk)

Z-Score (Altman; <1.81 = distress)

Per Share Metrics

Turnover & Efficiency Analysis (days)

Expense Ratios

Working Capital Analysis

Valuation Multiples

Cash-Flow Multiples

Enterprise Value Multiples

52-Week Range

Trailing Returns

ROIC vs WACC

Yields

Capital Deployment Yields

Liquidity & Leverage Ratios

Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)

EPS (Diluted)
$9
Book Value Per Share
$54
Free Cash Flow Per Share
$12
Cash Per Share
$3
Revenue Per Share
$77
OCF Per Share
$12
Return on Equity
17.8%
Return on Assets
10.6%
Return on Invested Capital
14.0%
Debt to Equity
0.32
Current Ratio
2.68
Quick Ratio
1.52
Asset Turnover
0.94
Days Sales Outstanding
50.21
Days Payables Outstanding
20.50
Days Inventory On Hand
73.32
Cash Conversion Cycle
103.02
R&D / Revenue
1.4%
SBC / Revenue
1.5%
Capex / Revenue
1.9%
Working Capital
$126M
Net Current Asset Value
$-30M
Invested Capital
$559M
OCF / Net Income
1.35
FCF / Net Income
1.35
Accruals Ratio (Sloan)
-3.6%
Net Debt
$115M
Net Debt / EBITDA
1.03
Interest Coverage
9.42
Cash Coverage
9.37
Capex Coverage
6.90
Tangible Common Equity
$86M
TCE / Total Assets
13.1%
Goodwill / Total Assets
30.1%
NOPAT
$76M
Cash ROIC
16.8%
WC / Revenue
20.9%
Capex / D&A
0.66
Reinvestment Rate
-4.8%
Total Payout Ratio
Asset Growth vs Revenue Growth
-15.4%
Revenue 5Y CAGR
27.4%
EPS 5Y CAGR
38.6%
FCF 5Y CAGR
34.8%
EBITDA 5Y CAGR
34.9%
Book Value 5Y CAGR
19.1%
Stock Price (FY-end)
$222
Market Cap
$1.73B
P/E Ratio
25.36
P/S Ratio
2.87
P/B Ratio
4.09
P/TB Ratio
20.24
P/OCF Ratio
18.85
P/FCF Ratio
18.85
Enterprise Value
$1.85B
EV / EBITDA
16.57
EV / Sales
3.07
EV / FCF
20.11
FCF Yield
5.3%
Shareholder Yield
-0.5%
Buyback Yield
R&D Yield
0.5%
Capex Yield
0.5%
Operating Leverage
0.73
Graham Number
$103
Shares Variation (YoY)
0.2%
Beta (5Y)
0.91
Cost of Equity
9.0%
Cost of Debt (after tax)
6.0%
WACC
8.8%
ROIC - WACC Spread
5.2%
52W High
$285
52W Low
$185
Trailing Return 1Y
-10.1%
Trailing Return 5Y
382.4%
F-Score (Piotroski)
7.00
M-Score (Beneish)
-2.55
Z-Score (Altman)
6.91

Earnings Forecasts

Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).

Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.

EPS — Consensus vs Actual

Revenue — Consensus vs Actual

Stock Price on Earnings Dates

UFP TECHNOLOGIES, INC. — Effective Tax Rate ReconciliationNEW

Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.

Effective Rate Trend

Reconciliation LineFY2020FY2021FY2022FY2023FY2024FY2025
Federal Statutory Rate21.00%21.00%21.00%21.00%21.00%21.00%
State & Local Income Taxes4.20%4.00%3.20%2.40%2.90%2.30%
Foreign Rate Differential0.00%0.00%3.70%9.30%7.70%
Other Adjustments0.20%0.80%-0.10%1.80%0.90%
R&D Tax Credits
FDII Deduction0.00%0.00%0.70%0.50%
SBC (Nondeductible)0.00%-1.90%-1.80%-1.10%
Valuation Allowance Change0.00%0.20%0.00%0.00%0.00%0.00%
Tax Law Change
Qualified Production Activities (Legacy DPAD)
Effective Tax Rate17.90%25.10%20.70%16.70%19.20%17.20%

Cash vs Accrual

ItemFY2020FY2021FY2022FY2023FY2024FY2025
Income Tax Expense (Accrual)$2.9M$5.3M$10.9M$9.0M$14.0M$14.2M
Income Taxes Paid (Cash)$2.5M$5.9M$13.2M$10.6M$12.8M$3.6M

UFP TECHNOLOGIES, INC. — M&A AcquisitionsNEW

Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.

AJR Enterprises LLC

Total Consideration

$110.0M

Purchase-Price Allocation

Goodwill

$35.6M

Assets Acquired

$124.1M

Liabilities Assumed

$10.3M

AQF

Total Consideration

$43.0M

Purchase-Price Allocation

Goodwill

$22.9M

Assets Acquired

$57.6M

Liabilities Assumed

$6.5M

Deferred Tax Liability

$2.3M

Welch Fluorocarbon Inc

Total Consideration

$34.6M

Purchase-Price Allocation

Goodwill

$17.1M

Assets Acquired

$39.6M

Liabilities Assumed

$596.0K

Contingent Earn-Out

Universal Plastics And Engineering Company Inc

Total Consideration

$7.5M

Purchase-Price Allocation

Goodwill

$3.2M

Assets Acquired

$7.9M

Liabilities Assumed

$110.0K

Marble Medical Inc

Total Consideration

$4.5M

Purchase-Price Allocation

Goodwill

$2.6M

Assets Acquired

$6.4M

Liabilities Assumed

$560.0K

Contingent Earn-Out

$400.0K

Techno Plastics Industries Inc

Total Consideration

$4.5M

Purchase-Price Allocation

Goodwill

$1.1M

Assets Acquired

$9.3M

Liabilities Assumed

$2.8M

Deferred Tax Liability

$461.0K

AJR Specialty Products And AJR Custom Foam Products

Total Consideration

$2.8M

Das Medical

Marble Medical Inc AJR Enterprises LLC Welch Flourocarbon Inc And AQF

Pro-Forma Combined Entity

Revenue

$610.5M

Net Income

+$69.6M

Diluted EPS

$8.92

Welch Fluorocarbon Inc.Marble Medical And DAS Medical